Qualifacts and Greenspace Health Announce Strategic Partnership to Advance Measurement-Based Care in Behavioral Health
New Integration Brings Measurement-Based Care Directly into Qualifacts EHRs, Enhancing Clinical Insight and Client Outcomes
Together, Qualifacts and Greenspace are delivering an industry-leading MBC experience that optimizes workflows, enhances client engagement, and provides meaningful data to inform care decisions and drive continuous quality improvement.
Integrated with Qualifacts EHRs, Greenspace's Measurement-Based Care Platform optimizes the collection and analysis of evidence-based assessments, allowing clinicians to consistently track client progress without manual data entry or the ne
NASHVILLE, TN & Toronto, ON, May 19, 2025 (GLOBE NEWSWIRE) -- Qualifacts, the leading provider of end-to-end electronic health record (EHR) software and data solutions for behavioral health and human services organizations, today announced a strategic integration partnership with Greenspace Health, the market leader in Measurement-Based Care (MBC) technology and implementation. This collaboration embeds Greenspace's MBC platform directly into Qualifacts' Credible and CareLogic EHR solutions, empowering providers to seamlessly measure client progress and improve clinical outcomes, without adding complexity to clinician workflows. With integration plans for Qualifacts' InSync EHR also underway, MBC will soon be available across all Qualifacts EHRs.
Together, Qualifacts and Greenspace are delivering an industry-leading MBC experience that optimizes workflows, enhances client engagement, and provides meaningful data to inform care decisions and drive continuous quality improvement. This integration also helps organizations meet key standards set by accrediting bodies, such as CARF and the Joint Commission, by embedding routine outcome measurement directly into clinical workflows. With automated assessment delivery and real-time insights across clients, clinicians, and programs, organizations can continually enhance the quality of care they deliver, while staying aligned with evolving accreditation requirements.
'Our mission has always been to deliver innovative, trusted tools that empower our clients to improve care quality and outcomes,' said Josh Schoeller, CEO at Qualifacts. 'This integration reflects our mission in action, embedding Greenspace's proven MBC solution directly into our EHR workflows. It reduces complexity for providers, empowers more informed care decisions, and helps organizations meet evolving quality standards. Many of our customers have already experienced the value of Greenspace, and we're excited to deepen that impact through a seamless, fully integrated experience.'
Integrated with Qualifacts EHRs, Greenspace's Measurement-Based Care Platform optimizes the collection and analysis of evidence-based assessments, allowing clinicians to consistently track client progress without manual data entry or the need for external tools.
Key benefits of the integration include:
Automated MBC Workflows: Client data, assessment schedules and progress tracking are automatically synced with the organization's EHR, reducing manual work and saving valuable clinical and administrative time.
Comprehensive Library of Evidence-Based Assessments: Providers can access more than 500 validated, evidence-based assessments.
Flexible Assessment Completion: Clients can complete assessments during or outside of sessions without needing to log in, driving higher completion rates and more reliable data to inform treatment decisions, clinical discussions, and quality improvement efforts.
Clinically-Meaningful Measurement: Providers can access real-time result visualizations and actionable insights directly in their EHR, supporting timely treatment decisions and data-informed care planning.
Real-Time Analytics and Outcome Dashboards: Clinical leaders are empowered with actionable data to identify off-track or at-risk clients, monitor clinician engagement and track program effectiveness. These insights support early intervention, clinical supervision, quality improvement and reporting for value-based care and accreditation.
'We're excited to partner with Qualifacts to expand access to Measurement-Based Care and enhance its impact for providers and the communities they support," said Jeremy Weisz, CEO of Greenspace Health. 'By integrating Greenspace directly into Qualifacts' EHR platforms, we're helping organizations consistently measure what matters most, while giving clinicians and clinical leaders the tools and information they need to deliver high-quality care, all in one place. With the EHR as their single source of clinical insight, providers can drive better outcomes with greater efficiency and confidence.'
Behavioral health organizations interested in implementing MBC through a Qualifacts integration are encouraged to attend our upcoming webinar, 'Measurement-Based Care in Practice: Impact and Strategies for Implementation,' on Tuesday, June 17, at 2pm CT.
ABOUT QUALIFACTS
Celebrating 25 years, Qualifacts is the leading provider of electronic health record (EHR) software and data solutions designed specifically for behavioral health and human services organizations. Putting the health of individuals first, our award-winning, AI-powered EHR platforms—Credible, CareLogic, and InSync—enable behavioral health providers to spend more time on what matters most: delivering superior care that drives better outcomes. Qualifacts is more than a provider of innovative technology—we're partners in care, working alongside organizations of all sizes nationwide to simplify the lives of behavioral health providers. We simplify clinical workflows and ensure compliance, while strengthening client-provider relationships. Today, we serve more than 2,700 organizations across all 50 states, including 33% of the nation's Certified Community Behavioral Health Centers (CCBHCs), supporting both non-profit and for-profit organizations in delivering superior behavioral healthcare.
ABOUT GREENSPACE HEALTH
Greenspace transforms mental health services by improving the way that behavioral healthcare is accessed, measured and delivered. Their Measurement-Based Care Platforms enable mental health providers and organizations to implement consistent, evidence-based measurement (often referred to as routine patient-reported outcome measures or PROMs) into their practice. This model is proven to significantly improve patient results while generating valuable data for organizations to enhance their quality of care. Greenspace's MBC solutions have been implemented across over 500 community and private clinics, hospitals, payors, insurers and healthcare systems, improving the patient experience and driving better-coordinated care and outcomes. To learn more about MBC, please visit greenspacehealth.com.
Attachments
Together, Qualifacts and Greenspace are delivering an industry-leading MBC experience that optimizes workflows, enhances client engagement, and provides meaningful data to inform care decisions and drive continuous quality improvement.
Integrated with Qualifacts EHRs, Greenspace's Measurement-Based Care Platform optimizes the collection and analysis of evidence-based assessments, allowing clinicians to consistently track client progress without manual data entry or the ne
CONTACT: Tristan Galvan Qualifacts tristan.galvan@qualifacts.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO, May 30, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions to advance precision oncology. "At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine." Research highlights include: Oral Presentation (1506): A technology-enabled clinical trial program's impact on patient screening and trial enrollment in 2024 Date/Time: Monday, June 2 from 3:00 PM–6:00 PM CDT Overview: The TIME network utilized algorithmic screening technology combined with nurse match review to screen over 1.28 million patients for clinical trials in 2024, resulting in 573 total consents - an average of 1.57 consents per day. The network's programmatic screening at scale, Tempus nurse review, and rapid activation processes helps increase patient access to trials. Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT Overview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery. Poster Presentation (499/11160): Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients Date/Time: Saturday, May 31 from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs into a structured format suitable for analysis. Tempus utilized a two-stage LLM system to abstract critical clinical data of NSCLC patients, achieving high agreement with human abstractors across various data domains. Poster Presentation (148/6532): Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval Date/Time: Sunday, June 1 at 9:00 AM–12:00 PM CDT Overview: Tempus xH, a whole genome sequencing assay for hematologic malignancies, enables highly sensitive detection of KMT2A-PTDs in AML—unlocking access to targeted therapies like revumenib. xH helps identify patients who may benefit from emerging treatments and equips clinicians with the insights they need. Poster Presentation (20/2558): A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Sunday, June 1 at 1:30 PM–4:30 PM CDT Overview: Tempus xM, a tumor-naive test, monitors treatment response by tracking ctDNA dynamics over time. Patients classified as a molecular non-responder at at least one timepoint while on immunotherapy had worse overall survival than molecular responders or patients with no ctDNA detected, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. To learn more about Tempus at ASCO, click here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Erin Carronmedia@
Business Wire
3 days ago
- Business Wire
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions to advance precision oncology. 'At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients,' said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. 'We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine.' Research highlights include: Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT Overview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery. Poster Presentation (499/11160): Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients Date/Time: Saturday, May 31 from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs into a structured format suitable for analysis. Tempus utilized a two-stage LLM system to abstract critical clinical data of NSCLC patients, achieving high agreement with human abstractors across various data domains. Poster Presentation (148/6532): Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval Date/Time: Sunday, June 1 at 9:00 AM–12:00 PM CDT Overview: Tempus xH, a whole genome sequencing assay for hematologic malignancies, enables highly sensitive detection of KMT2A-PTDs in AML—unlocking access to targeted therapies like revumenib. xH helps identify patients who may benefit from emerging treatments and equips clinicians with the insights they need. Poster Presentation (20/2558): A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Sunday, June 1 at 1:30 PM–4:30 PM CDT Overview: Tempus xM, a tumor-naive test, monitors treatment response by tracking ctDNA dynamics over time. Patients classified as a molecular non-responder at at least one timepoint while on immunotherapy had worse overall survival than molecular responders or patients with no ctDNA detected, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. To learn more about Tempus at ASCO, click here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Yahoo
3 days ago
- Yahoo
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO, May 30, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions to advance precision oncology. "At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine." Research highlights include: Oral Presentation (1506): A technology-enabled clinical trial program's impact on patient screening and trial enrollment in 2024 Date/Time: Monday, June 2 from 3:00 PM–6:00 PM CDT Overview: The TIME network utilized algorithmic screening technology combined with nurse match review to screen over 1.28 million patients for clinical trials in 2024, resulting in 573 total consents - an average of 1.57 consents per day. The network's programmatic screening at scale, Tempus nurse review, and rapid activation processes helps increase patient access to trials. Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT Overview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery. Poster Presentation (499/11160): Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients Date/Time: Saturday, May 31 from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs into a structured format suitable for analysis. Tempus utilized a two-stage LLM system to abstract critical clinical data of NSCLC patients, achieving high agreement with human abstractors across various data domains. Poster Presentation (148/6532): Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval Date/Time: Sunday, June 1 at 9:00 AM–12:00 PM CDT Overview: Tempus xH, a whole genome sequencing assay for hematologic malignancies, enables highly sensitive detection of KMT2A-PTDs in AML—unlocking access to targeted therapies like revumenib. xH helps identify patients who may benefit from emerging treatments and equips clinicians with the insights they need. Poster Presentation (20/2558): A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Sunday, June 1 at 1:30 PM–4:30 PM CDT Overview: Tempus xM, a tumor-naive test, monitors treatment response by tracking ctDNA dynamics over time. Patients classified as a molecular non-responder at at least one timepoint while on immunotherapy had worse overall survival than molecular responders or patients with no ctDNA detected, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. To learn more about Tempus at ASCO, click here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Erin Carronmedia@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
